Technical Analysis for JANX - Janux Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Earnings Movers | Other | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Fell Below 20 DMA | Bearish | -5.81% | |
MACD Bearish Signal Line Cross | Bearish | -5.81% | |
Wide Bands | Range Expansion | -5.81% |
Alert | Time |
---|---|
Down 3% | about 24 hours ago |
Fell Below Previous Day's Low | about 24 hours ago |
Down 2 % | 1 day ago |
Down 1% | 1 day ago |
20 DMA Resistance | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 65.6 |
52 Week Low | 5.65 |
Average Volume | 794,927 |
200-Day Moving Average | 19.30 |
50-Day Moving Average | 45.50 |
20-Day Moving Average | 53.38 |
10-Day Moving Average | 57.84 |
Average True Range | 5.08 |
RSI (14) | 46.81 |
ADX | 38.21 |
+DI | 24.85 |
-DI | 22.77 |
Chandelier Exit (Long, 3 ATRs) | 50.37 |
Chandelier Exit (Short, 3 ATRs) | 59.94 |
Upper Bollinger Bands | 64.72 |
Lower Bollinger Band | 42.05 |
Percent B (%b) | 0.3 |
BandWidth | 42.46 |
MACD Line | 3.62 |
MACD Signal Line | 4.65 |
MACD Histogram | -1.0262 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 56.42 | ||||
Resistance 3 (R3) | 57.13 | 55.33 | 55.17 | ||
Resistance 2 (R2) | 55.33 | 53.42 | 54.98 | 54.75 | |
Resistance 1 (R1) | 52.13 | 52.24 | 51.23 | 51.42 | 54.34 |
Pivot Point | 50.33 | 50.33 | 49.89 | 49.98 | 50.33 |
Support 1 (S1) | 47.13 | 48.42 | 46.23 | 46.42 | 43.50 |
Support 2 (S2) | 45.33 | 47.24 | 44.98 | 43.09 | |
Support 3 (S3) | 42.13 | 45.33 | 42.67 | ||
Support 4 (S4) | 41.42 |